GlassScriptPhysician profile
Ranjodh Singh
NPI 1013161538
$5,764.15
in general payments reported to CMS, 2019-2025
28 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 85% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $111 · 2021: $969 · 2022: $300 · 2023: $448 · 2024: $1,098 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,483 · Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,483.00 |
| Food and Beverage | $1,689.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $2,252.65 | 2025 | Phasix Mesh |
| Stryker Corporation | $844.76 | 2021 | |
| Intuitive Surgical, INC. | $836.14 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $230.74 | 2019-2025 | Imfinzi, Calquence |
| Janssen Biotech, INC. | $191.70 | 2019-2024 | Darzalex, Erleada, Talvey |
| Merck Sharp & Dohme LLC | $191.11 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $170.61 | 2020-2025 | Enhertu, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $169.58 | 2019-2023 | Imbruvica |
| Abbvie INC. | $134.76 | 2024-2025 | |
| Ethicon US, LLC | $105.40 | 2019-2021 | |
| Amgen INC. | $98.74 | 2019-2023 | Vectibix, Nplate |
| Novartis Pharmaceuticals Corporation | $86.63 | 2022-2025 | |
| Braintree Laboratories, INC. | $70.31 | 2021-2023 | Sutab |
| Eisai INC. | $68.11 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $56.91 | 2022-2023 | Libtayo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $46.17 | 2019-2020 | |
| Seagen INC. | $26.50 | 2023 | Tukysa |
| Mirati Therapeutics, INC. | $21.79 | 2024 | Krazati |
| Exelixis INC. | $20.64 | 2025 | Cabometyx |
| Organogenesis INC. | $20.01 | 2023 | Puraply |
| G1 Therapeutics, INC. | $17.93 | 2023 | Cosela |
| Caris Mpi, INC. | $16.70 | 2025 | Mi Cancer Seek |
| Adaptive Biotechnologies Corporation | $15.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.30 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.08 | 2019 | |
| Emd Serono, INC. | $13.64 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $13.62 | 2021 | |
| Puma Biotechnology, INC. | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjodh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.